Colgate-Palmolive (CL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks
Open on Zacks
Colgate-Palmolive (CL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2026, Colgate-Palmolive (CL) reported revenue of $5.37 billion, up 4.6% over the same period last year. EPS came in at $0.97, compared to $0.91 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $5.33 billion, representing a surprise of +0.72%. The company delivered an EPS surprise of +5.44%, with the consensus EPS estimate being $0.92.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Oral, Personal and Home Care- North America: $905 million compared to the $916.4 million average estimate based on five analysts. The reported number represents a change of -9.4% year over year. Net Sales- Oral, Personal and Home Care- Asia Pacific: $802 million versus $791.16 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12.3% change. Net Sales- Oral, Personal and Home Care- Europe, Middle East & Africa: $1.13 billion versus the five-analyst average estimate of $1.15 billion. The reported number represents a year-over-year change of +41.1%. Net Sales- Oral, Personal and Home Care- Latin America: $1.33 billion versus the five-analyst average estimate of $1.3 billion. The reported number represents a year-over-year change of +12.6%. Net Sales- Pet Nutrition: $1.21 billion versus the five-analyst average estimate of $1.19 billion. The reported number represents a year-over-year change of +5.5%. Net Sales- Total Oral, Personal and Home Care: $4.16 billion versus the five-analyst average estimate of $4.16 billion. The reported number represents a year-over-year change of +4.4%. Operating profit- Pet Nutrition: $267 million versus the three-analyst average estimate of $263.02 million. Operating profit- Total Oral, Personal and Home Care: $1.04 billion compared to the $1.01 billion average estimate based on three analysts.

View all Key Company Metrics for Colgate-Palmolive here>>>

Shares of Colgate-Palmolive have returned +10.2% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Colgate-Palmolive Company (CL): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research